Trials:

1. Altamura AC, et al. J Affect Disord 2003;76:267-71.
2. Brecher M and Huizar K. European Neuropsychopharmacology. The Journal of the European College of Neuropsychopharmacology 2003;13(Suppl 4):S337.
3. Fleck DE, et al. American College of Neuropsychopharmacology: 42nd Annual Meeting 2003 [Congress poster].
4. Jones M and Huizar K. Presented at ICBP, Sydney, Australia 2004.[Congress poster]
5. Mullen JA, et al. Presented at ICBP, Sydney, Australia 2004.[Congress poster]
6. Paulsson B and Huizar K. Presented at ICBP, Sydney, Australia 2004.[Congress poster]
7. Sajatovic M, et al.; J Clin Psychiatry 2002;63:1156-63.
8. Strakowski SM, et al. 42nd ACNP annual meeting 2003 [Congress poster].
9. Tacchini G, et al. World J Biol Psychiatry 2004;5(Suppl 1):52. [Congress paper]

• WFSBP:
  Grunze, et al. World J Biol Psychiatry 2003; 4:5-13.
• Danish Guidelines:
  Licht, et al. Acta Psychiatr Scand 2003;108(S419):1-22. 
• Australian Guidelines:
  Mitchell PB, et al. Australasian Psychiatry 11(1):39-53.
• BAP Guidelines:
  Goodwin, et al. J Psychopharmacol 2003;17:149-73.
• APA Guidelines:
  Hirschfeld, et al. Am J Psychiatry 2002;159(4 Suppl):1-50.
• ICG Guidelines:
  J Clin Psychiatry 2004;65:(In press).